Biostability and biological performance of a PDMS-based polyurethane for controlled drug release

Biomaterials

Volumn 29, Issue 20, 2008, Pages 2987-2995

  Simmons, Anne ^a   Padsalgikar, Ajay Devidas ^b   Ferris, Lynn Marie ^a   Poole Warren, Laura Anne ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b AorTech Biomaterials Pty Ltd   (Australia)

Author keywords

Biostability; Drug delivery; In vitro test; In vivo test; Polydimethylsiloxane; Polyurethane

Indexed keywords

DRUG DELIVERY; MATHEMATICAL MODELS; POLYDIMETHYLSILOXANE; SCANNING ELECTRON MICROSCOPY;

BIOSTABILITY; IN VITRO TEST; IN VIVO TEST;

POLYURETHANES;

DEXAMETHASONE ACETATE; DIMETICONE; ELASTOMER; POLYURETHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY TEST; HISTOLOGY; IMPLANTATION; INFRARED SPECTROSCOPY; LEACHING; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SHEEP; TENSILE STRENGTH;

BIOCOMPATIBLE MATERIALS; DEXAMETHASONE; DIMETHYLPOLYSILOXANES; DRUG DELIVERY SYSTEMS; MICROSCOPY, ELECTRON, SCANNING; NYLONS; POLYURETHANES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

OVIS;

EID: 42749088988     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.04.007     Document Type: Article

References (38)

1. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl J Med 350 (2004) 221-231
2. Schampaert E., Moses J.W., Schofer J., Schluter M., Gershlick A.H., Cohen E.A., et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 (2006) 36-41
3. Aoki J., Colombo A., Dudek D., Banning A.P., Drzewiecki J., Zmudka K., et al. Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation - insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 112 (2005) 3876-3883
4. Fujii K., Carlier S.G., Mintz G.S., Yang Y.M., Moussa I., Weisz G., et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. J Am Coll Cardiol 45 (2005) 995-998
5. Pfisterer M., Rocca H.P.B.L., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents - an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
6. Serruys P.W., Kutryk M.J.B., and Ong A.T.L. Drug therapy - coronary-artery stents. New Engl J Med 354 (2006) 483-495
7. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
8. Bartorelli A.L., Trabattoni D., Fabbiocchi F., Montorsi P., de Martini S., Calligaris G., et al. Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J Interv Cardiol 16 (2003) 499-505
9. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serruys P.W., Holmes Jr. D.R., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 (1996) 1690-1697
10. Virmani R., Liistro F., Stankovic G., Di Mario C., Montorfano M., Farb A., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
11. Grube E., Lansky A., Hauptmann K.E., Di Mario C., Di Sciascio G., Colombo A., et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization - one-year results from the SCORE randomized trial. J Am Coll Cardiol 44 (2004) 1368-1372
12. Nebeker J.R., Virmani R., Bennett C.L., Hoffman J.M., Samore M.H., Alvarez J., et al. Hypersensitivity cases associated with drug-eluting coronary stents - a review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
13. Finn A.V., Nakazawa G., Joner M., Kolodgie F.D., Mont E.K., Gold H.K., et al. Vascular responses to drug eluting stents - importance of delayed healing. Arterioscl Throm Vas 27 (2007) 1500-1510
14. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans - delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
15. Luscher T.F., Steffel J., Eberli F.R., Joner M., Nakazawa G., Tanner F.C., et al. Drug-eluting stent and coronary thrombosis - biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
16. Bostman O.M. Intense granulomatous inflammatory lesions associated with absorbable internal-fixation devices made of polyglycolide in ankle fractures. Clin Orthop Relat Res 278 (1992) 193-199
17. Taylor M.S., Daniels A.U., Andriano K.P., and Heller J. Six bioabsorbable polymers - in vitro acute toxicity of accumulated degradation products. J Appl Biomaterials 5 (1994) 151-157
18. Villa A.E., Guzman L.A., Chen W., Golomb G., Levy R.J., and Topol E.J. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 93 (1994) 1243-1249
19. Simmons A., Hyvarinen J., Odell R.A., Martin D.J., Gunatillake P.A., Noble K.R., et al. Long term in vivo biostability of poly(dimethylsiloxane)/poly(hexamethylene oxide) mixed macrodiol-based polyurethane elastomers. Biomaterials 25 (2004) 4887-4900
20. Tepe G., Schmehl J., Wendel H.P., Schaffner S., Heller S., Gianotti M., et al. Reduced thrombogenicity of nitinol stents - in vitro evaluation of different surface modifications and coatings. Biomaterials 27 (2006) 643-650
21. Collier T., Tan J., Shive M., Hasan S., Hiltner A., and Anderson J. Biocompatibility of poly(ether urethane urea) containing dehydroepiandrosterone. J Biomed Mater Res 41 (1998) 192-201
22. Wu Y., Zhao Q., Anderson J.M., Hiltner A., Lodoen G.A., and Payet C.R. Effect of some additives on the biostability of a poly(ether urethane) elastomer. J Biomed Mater Res 25 (1991) 725-739
23. Schubert M.A., Wiggins M.J., Anderson J.M., and Hiltner A. Comparison of two antioxidants for poly(ether urethane urea) in an accelerated in vitro biodegradation system. J Biomed Mater Res 34 (1997) 493-505
24. Brunstedt M.R., Ziats N.P., Robertson S.P., Hiltner A., Anderson J.M., Lodoen G.A., et al. Protein adsorption to poly(ether urethane ureas) modified with acrylate and methacrylate polymer and copolymer additives. J Biomed Mater Res 27 (1993) 367-377
25. Park J.H., Lee K.B., Kwon I.C., and Bae Y.H. PDMS-based polyurethanes with MPEG grafts: mechanical properties, bacterial repellency, and release behavior of rifampicin. J Biomater Sci 12 (2001) 629-645
26. Martin D.J., Poole-Warren L.A., Gunatillake P.A., McCarthy S.J., Meijs G.F., and Schindhelm K. Polydimethylsiloxane/polyether-mixed macrodiol-based polyurethane elastomers: biostability. Biomaterials 21 (2000) 1021-1029
27. Dillon J.G. Infrared spectroscopic atlas of polyurethanes (1989), Technomic Publishing, Lancaster, Pennsylvania
28. McCarthy S.J., Meijs G.F., Mitchell N., Gunatillake P.A., Heath G., Brandwood A., et al. In-vivo degradation of polyurethanes: transmission-FTIR microscopic characterization of polyurethanes sectioned by cryomicrotomy. Biomaterials 18 (1997) 1387-1409
29. SDBS library of IR spectra. Japan: AIST; 4 January 2007.
30. Gorog S. Recent advances in the analysis of steroid hormones and related drugs. Anal Sci 20 (2004) 767-782
31. Bundgaard H., and Hansen J. Studies on the stability of corticosteroids. Arch Pharm Chem Sci Ed 8 (1980) 187-206
32. Casas J., Zhao Q., Donovan M., Schroeder P., Stokes K., and Untereker D. In vitro modulation of macrophage phenotype and inhibition of polymer degradation by dexamethasone in a human macrophage/Fe/stress system. J Biomed Mater Res 46 (1999) 475-484
33. Thompson E.B., Medh R.D., Zhou F., Ayala-Torres S., Ansari N., Zhang W., et al. Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc. J Ster Biochem Mol Biol 69 (1999) 453-461
34. Rose A.L., Smith B.E., and Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100 (2002) 1765-1773
35. Liu X., Huang Y., Hanet C., Vandormael M., Legrand V., Dens J., et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 60 (2003) 172-179
36. Lincoff A.M., Furst J.G., Ellis S.G., Tuch R.J., and Topol E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29 (1997) 808-816
37. Hickey T., Kreutzer D., Burgess D.J., and Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res 61 (2002) 180-187
38. Stevens K.R., Einerson N.J., Burmania J.A., and Kao W.J. In vivo biocompatibility of gelatin-based hydrogels and interpenetrating networks. J Biomater Sci 13 (2002) 1353-1366